J. Woynarowski

发表

7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents.

D. V. Von Hoff, B. Vladu, J. Woynarowski, 2000, Molecular pharmacology.

Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells.

T. Beerman, J. Woynarowski, 1997, Biochimica et biophysica acta.

Targeting Apoptosis by Hydroxymethylacylfulvene in Combination with Gamma Radiation in Prostate Tumor Cells

T. Herman, J. Woynarowski, J. Macdonald, 2000, Radiation research.

Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.

Huiyun Liang, J. Woynarowski, S. Waters, 2003, Biochemical pharmacology.

DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.

S. Faivre, J. Woynarowski, D. Chan, 2003, Biochemical pharmacology.

Preferential targeting of apoptosis in tumor versus normal cells.

J. Woynarowski, B. Woynarowska, 2002, Biochimica et biophysica acta.

Cellular and Molecular Pharmacology of Oxaliplatin 1

E. Raymond, S. Chaney, S. Faivre, 2002 .

Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

C. Napier, Walter G Chapman, J. Woynarowski, 1998, Molecular pharmacology.

Oxaliplatin-induced damage of cellular DNA.

E. Raymond, S. Chaney, S. Faivre, 2000, Molecular pharmacology.

Resistance of CHO cells expressing P-glycoprotein to cyclopropylpyrroloindole (CPI) alkylating agents.

T. Beerman, J. Woynarowski, R. Baker, 1992, Biochemical pharmacology.

Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 leukemia cells.

L. Szmigiero, T. Beerman, J. Woynarowski, 1989, Biochemical pharmacology.

Targeting critical regions in genomic DNA with AT-specific anticancer drugs.

J. Woynarowski, 2002, Biochimica et biophysica acta.

Induction of heat-labile sites in DNA of mammalian cells by the antitumor alkylating drug CC-1065.

L. Gawron, T. Beerman, J. Woynarowski, 1991, Biochemistry.

Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines

E. Raymond, S. Faivre, E. Cvitkovic, 1999, Cancer Chemotherapy and Pharmacology.

Preferential damage to defined regions of genomic DNA by AT-specific anticancer drugs

J. Woynarowski, 2002 .

WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.

Z. Estrov, D. Harris, H. Kantarjian, 2001, Anticancer research.

Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells

T. Herman, J. Woynarowski, S. Waters, 2004, Cancer biology & therapy.

Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).

J. Woynarowski, J. Macdonald, B. Woynarowska, 2000, Biochemical pharmacology.

The estimation of molecular weights of basic proteins (histones) by gel filtration in 6 M guanidine hydrochloride solution.

J. Woynarowski, J. Konopa, 1973, Journal of chromatography.

DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.

T. Beerman, E. Ferrazzí, D. Brenner, 1991, Cancer communications.

Effect of minor groove binding drugs on mammalian topoisomerase I activity.

M. McHugh, T. Beerman, R. Sigmund, 1989, Biochemical pharmacology.

DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells.

T. Beerman, R. Sigmund, J. Woynarowski, 1989, Biochemistry.

Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole.

M. McHugh, T. Beerman, R. Sigmund, 1989, Molecular pharmacology.

CC-1065 bonding to intracellular and purified SV40 DNA: site specificity and functional effects.

M. McHugh, L. Gawron, T. Beerman, 1994, Biochemistry.

DNA damage in HeLa s3 cells by an antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines.

A. Bartoszek, J. Woynarowski, J. Konopa, 1984, Chemico-biological interactions.

Purification and characterization of macromomycin-I, a protein antibiotic containing a non-protein chromophore.

T. Beerman, J. Woynarowski, 1980, Biochemical and biophysical research communications.

Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones.

J. Woynarowski, J. Konopa, 1981, Molecular pharmacology.

Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.

T. Beerman, R. Sigmund, J. Woynarowski, 1988, Biochimica et biophysica acta.

Induction of AT-specific DNA-interstrand crosslinks by bizelesin in genomic and simian virus 40 DNA.

C. Napier, Walter G Chapman, J. Woynarowski, 1999, Biochimica et biophysica acta.

The mechanism of inhibition of DNA replication in HeLa S3 cells by the antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines.

A. Bartoszek, J. Woynarowski, 1985, Biochimica et biophysica acta.

Inhibition of DNA replication in HeLa S3 cells by macromomycin-I, an antitumor protein antibiotic.

T. Beerman, J. Woynarowski, 1980, Molecular pharmacology.

Interaction between DNA and viscotoxins. Cytotoxic basic polypeptides from Viscum album L.

J. Woynarowski, J. Konopa, 1980, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Isolation of viscotoxins. Cytotoxic basic polypeptides from Viscum album L.

J. Woynarowski, J. Konopa, M. Lewandowska-Gumieniak, 1980, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues.

T. Herman, W. Priebe, J. Woynarowski, 2004, Molecular cancer therapeutics.

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).

D. Troyer, C. Napier, J. Woynarowski, 1997, Biochemical pharmacology.

The Significance of Poly-Targeting in Apoptosis Induction by Alkylating Agents and Platinum Drugs

J. Woynarowski, B. Woynarowska, 2007 .

Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.

Huiyun Liang, T. Herman, C. Michejda, 2004, Molecular cancer therapeutics.

Irofulven Induces Apoptosis in Breast Cancer Cells Regardless of Caspase-3 Status*

Huiyun Liang, J. Woynarowski, B. Woynarowska, 2004, Breast Cancer Research and Treatment.

AT-rich Islands in Genomic DNA as a Novel Target for AT-specific DNA-reactive Antitumor Drugs* 210

C. Benham, S. Hardies, K. Rodriguez, 2001, The Journal of Biological Chemistry.

Cellular and molecular pharmacology of oxaliplatin.

E. Raymond, S. Chaney, S. Faivre, 2002, Molecular cancer therapeutics.

Preferential effect of bleomycin on newly replicated chromatin in nuclei from L1210 cells.

T. Beerman, J. Woynarowski, 1989, Biochimica et biophysica acta.

Matrix attachment region (MAR) properties and abnormal expansion of AT island minisatellites in FRA16B fragile sites in leukemic CEM cells.

T. Herman, J. Jackson, J. Woynarowski, 2003, Nucleic acids research.

Oxaliplatin: mechanism of action and antineoplastic activity.

E. Raymond, S. Chaney, S. Faivre, 1998, Seminars in oncology.

Enzymatic activity of endogenous telomerase associated with intact nuclei from human leukemia CEM cells.

J. Woynarowski, T. Fletcher, A. Trevino, 1999, Biochemical and biophysical research communications.

AT islands - their nature and potential for anticancer strategies.

J. Woynarowski, 2004, Current cancer drug targets.

Bleomycin-induced aggregation of presolubilized and nuclear chromatin from L1210 cells.

L. Gawron, T. Beerman, J. Woynarowski, 1987, Biochimica et biophysica acta.

Netropsin and bis-netropsin analogs as inhibitors of the catalytic activity of mammalian DNA topoisomerase II and topoisomerase cleavable complexes.

J. Lown,, L. Gawron, T. Beerman, 1991, Biochimica et biophysica acta.

Degradation of HeLa cell chromatin by neocarzinostatin and its chromophore.

M. McHugh, T. Beerman, J. Woynarowski, 1982, Biochimica et biophysica acta.

Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).

J. Woynarowski, J. Macdonald, M. Herzig, 1999, Biochemical pharmacology.

Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.

W. Denny, T. Beerman, J. Woynarowski, 1994, Anti-cancer drug design.

Erratum: Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells (Radiation Research (2000) 154:4 (429-438))

T. Herman, J. Woynarowski, J. Macdonald, 2000 .

Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs.

H. Ginsburg, M. Krugliak, J. Woynarowski, 2007, Molecular and biochemical parasitology.

Unwound nature of MAR-capable AT-rich DNA domains (AT-islands) targeted by a highly AT-specific drug bizelesin

P. Osmulski, M. Gaczynska, J. Jackson, 2006 .

The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level.

L. Hurley, K. Rodriguez, J. Woynarowski, 2002, Biochemistry.

Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity.

C. Napier, J. Woynarowski, A. Trevino, 2000, Biochemistry.

Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific.

J. Woynarowski, M. Herzig, A. Trevino, 1999, Biochemistry.

Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA.

M. McHugh, L. Gawron, T. Beerman, 1995, Biochemistry.

Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692.

Walter G Chapman, J. Woynarowski, M. Herzig, 1999, Anticancer research.

Targeting of redox-controlling proteins of the thioredoxin family by oxaliplatin

M. Losiewicz, J. Woynarowski, B. Woynarowska, 2005 .